Morgan Stanley set a €127.00 ($149.41) price objective on Merck KGaA (FRA:MRK) in a report issued on Monday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other equities research analysts also recently weighed in on MRK. Nord/LB set a €108.00 ($127.06) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. set a €110.00 ($129.41) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 6th. DZ Bank restated a buy rating on shares of Merck KGaA in a research report on Monday, August 10th. Independent Research set a €124.00 ($145.88) target price on Merck KGaA and gave the stock a buy rating in a research report on Friday, August 7th. Finally, Warburg Research set a €108.00 ($127.06) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. Merck KGaA currently has a consensus rating of Hold and a consensus target price of €113.69 ($133.76).

Shares of Merck KGaA stock opened at €124.30 ($146.24) on Monday. Merck KGaA has a 52 week low of €76.60 ($90.12) and a 52 week high of €115.00 ($135.29). The business’s fifty day simple moving average is €114.37 and its 200-day simple moving average is €106.30.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Capital Gains Distribution

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.